Analysis of Mental Medicine (MindMed) (NASDAQ: MNMD) and Mannatech (NASDAQ: MTEX)


Mind Medicine (MindMed) (NASDAQ: MNMD – Get Rating) and Mannatech (NASDAQ: MTEX ​​- Get Rating) are both small-cap medical companies, but which is the best investment? We will compare the two companies based on their risk strength, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares the net margins, return on equity and return on assets of Mind Medicine (MindMed) and Mannatech.

Net margins Return on equity return on assets
Mental Medicine (MindMed) N / A -55.27% -51.10%
mannatech 6.16% 39.51% 15.62%

Insider and Institutional Ownership

12.4% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 32.0% of Mannatech’s shares are held by institutional investors. 45.8% of Mannatech’s stock is held by company insiders. Strong institutional ownership indicates that hedge funds, large fund managers, and endowments believe a stock will outperform the market over the long term.

Analyst Notes

This is a breakdown of recent ratings and target prices for Mind Medicine (MindMed) and Mannatech, as reported by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Mental Medicine (MindMed) 0 0 3 0 3.00
mannatech 0 0 0 0 N / A

Mind Medicine (MindMed) currently has a consensus price target of 7.67, suggesting a potential upside of 882.91%. Given the higher likely benefit of Mind Medicine (MindMed), research analysts clearly believe that Mind Medicine (MindMed) is more favorable than Mannatech.

Benefits and evaluation

This table compares the gross revenue, earnings per share and valuation of Mind Medicine (MindMed) and Mannatech.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Mental Medicine (MindMed) N / A N / A -$93.04 million -0.23 -3.39
mannatech $159.76 million 0.33 $9.84 million $4.72 5.76

Mannatech has higher revenue and profit than Mind Medicine (MindMed). Mind Medicine (MindMed) trades at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Summary

Mannatech beats Mind Medicine (MindMed) on 9 of the 11 factors compared between the two stocks.

About Mental Medicine (MindMed) (Get an evaluation)

Mind Medicine (MindMed) Inc., a clinical-stage biopharmaceutical company, develops new products to treat brain health disorders related to psychiatry, addiction, pain and neurology. The Company is developing MM-120, which is in Phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed Phase 1 for the treatment of opioid withdrawal. It is also developing MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorders. The company is headquartered in Vancouver, Canada.

About Mannatech (Get an evaluation)

Mannatech, Incorporated operates as a worldwide health and wellness company. It develops, markets and sells nutritional supplements; topical and skin care and anti-aging products; and weight management products. The company primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.



Receive daily news and reviews for Mind Medicine (MindMed) – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com’s FREE daily newsletter.